Cropsolution has discovered and characterized novel human ACC inhibitors that are potent and specific, have favorable pharmacokinetic properties, and reduce fatty acid biosynthesis in rats.
Acetyl CoA Carboxylase (ACC) is a chemically and genetically validated target for treating obesity and Type II Diabetes.
Properties of CropsolutionÕs novel ACC inhibitors:
¥ IC50 < 10 nM against both human ACCs
¥ Highly specific for mammalian ACCs
¥ Active against both ACCs in cell-based assays
¥ Clean in Cell and Genetic toxicity assays
¥ Clean in Micronucleus assays
¥ Unlikely to be associated with QT prolongation (low hERG potency)
¥ Good oral bioavailability in rats
¥ Favorable and predictable pharmacokinetic properties in rats
¥ Reduce fatty acid biosynthesis in rats
¥ Improve key weight loss and insulin sensitivity biomarkers in rats in vivo
CropsolutionÕs proprietary ACC inhibitors are the subject of patent application WO/2010/008521
Cropsolution seeks to partner this ACC inhibitor drug program with a pharmaceutical or biotechnology company to advance this class of compounds into clinical trials.
For licensing inquiries:
P.O. Box 14069
Research Triangle Park, NC 27709 USA
+1 (919) 493-7452